Equities

Cosmo Pharmaceuticals NV

Cosmo Pharmaceuticals NV

Actions
  • Price (EUR)50.00
  • Today's Change1.60 / 3.31%
  • Shares traded100.00
  • 1 Year change-37.50%
  • Beta--
Data delayed at least 15 minutes, as of May 18 2022 13:46 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company. The Company develops therapies for gastrointestinal disorders. The Company's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. It has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.

  • Revenue in CHF (TTM)67.86m
  • Net income in CHF22.60m
  • Incorporated--
  • Employees290.00
  • Location
    Cosmo Pharmaceuticals NVRiverside II, Sir John Rogerson's QuayDUBLIN IrelandIRL
  • Phone+353 18170370
  • Websitehttp://www.cosmopharma.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
COPN:SWX since
announced
Transaction
value
Cassiopea SpAAnnounced04 Oct 202104 Oct 2021Announced-35.72%228.73m
Data delayed at least 15 minutes, as of May 18 2022 16:30 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.